Description
Baidyanath Kesari Kalp Royal Chyawanprash
Baidyanath Kesari Kalp Royal Chyawanprash is a Herbal Chyawanprash with saffron and gold-rich. The power of gold( Swarna Bhasma) alleviates its potency to cure diseases like weak immunity and fights weakness. The medicine strengthens the immune power that helps in fighting various ailments.
Product Description
Product: | Baidyanath Kesari Kalp Royal Chyawanprash. |
Ingredients: | Vanshlochan, Abhrak bhasma, Amla, Kesar, Ashwagandha, Safed Musli, Shatavari, White Sandal Wood, Elaichi, and Nagkesar. |
Formulated: | Paste. |
Quantity: | 1 Kg. |
Usage: | As per the doctor’s prescription. |
Ingredients
The ingredients of Baidyanath Kesari Kalp Royal Chyawanprash Vanshlochan, Abhrak bhasma, Amla, Kesar, Ashwagandha, Safed Musli, Shatavari, White Sandal Wood, Elaichi, and Nagkesar.
- Abhrak Bhasma – It has the potential to treat various kinds of diseases.
- Ashwagandha – It is an immunity builder and gives strength.
- Amla – It is enriched with Vitamin C, a major ingredient of the product.
The search for the best supplier of herbal Chyawanprash in Sweden.
Major Benefits of Baidyanath Kesari Kalp Royal Chyawanprash
- Chyawanprash is an excellent immunity booster that helps fight all disease-causing organisms.
- The presence of Ashwagandha helps in building stamina and also acts as a health rejuvenator.
- Kesar( saffron) is an excellent neuroprotectant that boosts neurological activities.
- It gives energy, strength, stamina, and immunity boost up.
- The product is Ayurvedic Medicine for old people to treats the problems of geriatric.
Precautions
- Read the instructions before use.
- Protect from direct sunlight.
- Keep in a cool dry place.
- Do not refrigerate.
- Close the lid tightly after use.
Dosage
Consume a tablespoon of Chyawanprash twice a day with lukewarm milk.
Side Effect
No reported side effects of the medicine are reported. In case any, stop using it immediately.
It is advisable to consult a doctor in case of pregnancy and lactation.
Reviews
There are no reviews yet.